Literature DB >> 24440043

Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer.

Gregory Vlacich1, Daniel E Spratt1, Roberto Diaz1, John G Phillips1, Jostin Crass1, Chung-I Li2, Yu Shyr2, Anthony J Cmelak3.   

Abstract

BACKGROUND AND
PURPOSE: To determine if dose and/or dose-volume parameters to anatomic swallowing structures are predictive of gastrostomy tube (PEG) dependence from chemotherapy-intensity modulated radiotherapy (IMRT) in locally advanced head and neck cancer (LAHNC). METHODS AND MATERIALS: A retrospective study was performed on 141 consecutive patients with LAHNC (squamous cell) treated with definitive chemoIMRT with weekly concurrent carboplatin and paclitaxel. Late dysphagia was assessed by length of PEG requirement. Analysis of IMRT dose was retrospectively performed for critical swallowing structures.
RESULTS: Approximately 62% of patients required PEG, the majority placed during treatment. Mean and median time for PEG was 7.7 and 4.4 months respectively (range 1.4-43.8). Only IMRT dose to the inferior constrictor was significantly associated with length of PEG. Mean dose (of individual mean doses) was 47 Gy for prolonged PEG use versus 41 Gy for PEG ⩽ 12 months. V40 to the inferior constrictor also correlated with PEG >12 months (p = 0.02) with a mean V40 of 48% versus 41% for PEG ⩽ 12 months.
CONCLUSIONS: IMRT dose to the inferior constrictor correlated with persistent dysphagia requiring prolonged PEG use. Maintaining mean inferior constrictor dose to ⩽ 41 Gy and V40 to ⩽ 41% may help minimize gastrostomy tube dependence.
Copyright © 2014. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Dysphagia; Head and neck; IMRT; PEG dependence; Squamous cell carcinoma

Mesh:

Year:  2014        PMID: 24440043     DOI: 10.1016/j.radonc.2013.12.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

1.  Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.

Authors:  Jeffrey M Vainshtein; Dominic H Moon; Felix Y Feng; Douglas B Chepeha; Avraham Eisbruch; Matthew H Stenmark
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

Review 2.  Impact of weight loss in patients with head and neck carcinoma undergoing radiotherapy: is it an underestimated phenomenon? A radiation oncologist's perspective.

Authors:  J Cacicedo; A Dal Pra; F Alongi; A Navarro
Journal:  Eur J Clin Nutr       Date:  2015-04-29       Impact factor: 4.016

3.  Predictive Factors for Prophylactic Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement and Use in Head and Neck Patients Following Intensity-Modulated Radiation Therapy (IMRT) Treatment: Concordance, Discrepancies, and the Role of Gabapentin.

Authors:  Wuyang Yang; Todd R McNutt; Sara A Dudley; Rachit Kumar; Heather M Starmer; Christine G Gourin; Joseph A Moore; Kimberly Evans; Mysha Allen; Nishant Agrawal; Jeremy D Richmon; Christine H Chung; Harry Quon
Journal:  Dysphagia       Date:  2016-01-11       Impact factor: 3.438

Review 4.  Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus.

Authors:  Jessica L Geiger; Jamie A Ku
Journal:  Curr Treat Options Oncol       Date:  2019-02-15

5.  Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy.

Authors: 
Journal:  Radiother Oncol       Date:  2016-02-17       Impact factor: 6.280

6.  Is there a patient population with squamous cell carcinoma of the head and neck region who might benefit from de-intensification of postoperative radiotherapy? : A monocentric retrospective analysis of a previously defined low-risk patient population treated with standard-of-care radiotherapy.

Authors:  Yonca Onbasi; Sebastian Lettmaier; Markus Hecht; Sabine Semrau; Heinrich Iro; Marco Kesting; Rainer Fietkau; Marlen Haderlein
Journal:  Strahlenther Onkol       Date:  2019-01-04       Impact factor: 3.621

7.  E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Authors:  Shanthi Marur; Shuli Li; Anthony J Cmelak; Maura L Gillison; Weiqiang J Zhao; Robert L Ferris; William H Westra; Jill Gilbert; Julie E Bauman; Lynne I Wagner; David R Trevarthen; Jahagirdar Balkrishna; Barbara A Murphy; Nishant Agrawal; A Dimitrios Colevas; Christine H Chung; Barbara Burtness
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

8.  Impact of dosimetric factors on long-term percutaneous enteral gastrostomy (PEG) tube dependence in head and neck cancer patients after (chemo)radiotherapy-results from a prospective randomized trial.

Authors:  Anastassia Löser; Maximilian Grohmann; Anna Finger; Franziska Greinert; Linda Krause; Isabel Molwitz; Andreas Krüll; Cordula Petersen
Journal:  Strahlenther Onkol       Date:  2022-08-25       Impact factor: 4.033

Review 9.  Treatment de-intensification strategies for head and neck cancer.

Authors:  Jacqueline R Kelly; Zain A Husain; Barbara Burtness
Journal:  Eur J Cancer       Date:  2016-10-15       Impact factor: 9.162

10.  DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.

Authors:  Imran Petkar; Keith Rooney; Justin W G Roe; Joanne M Patterson; David Bernstein; Justine M Tyler; Marie A Emson; James P Morden; Kathrin Mertens; Elizabeth Miles; Matthew Beasley; Tom Roques; Shreerang A Bhide; Kate L Newbold; Kevin J Harrington; Emma Hall; Christopher M Nutting
Journal:  BMC Cancer       Date:  2016-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.